Clinical significance of serum 7-ketocholesterol concentrations in the progression of coronary atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 4, 2009, Pages 363-370

  Hitsumoto, Takashi ^a   Takahashi, Mao ^a   Iizuka, Takuo ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

7 Ketocholesterol; Coronary angiography; Coronary artery disease; Oxysterol; Risk factor

Indexed keywords

7 OXOCHOLESTEROL; C REACTIVE PROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; STABLE ANGINA PECTORIS;

EID: 70450271117     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.No703     Document Type: Article

References (53)

1. Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ Res, 1999; 85: 753-766
2. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes, 1999; 48: 1-9
3. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, Awano K, Kobayashi K, Maeda K, Hata K, Shinke T, Kobayashi S, Hirata K, Kawashima S, Itabe H, Hayashi Y, Imajoh-Ohmi S, Itoh H, Yokoyama M: Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol, 2002; 22: 1838-1844
4. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 1997; 272: 20963-20966
5. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 2001; 103: 1955-1960
6. Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y: Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis, 2006; 184: 425-430
7. Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, Kukidome D, Wake N, Matsumura T, Miyamura N, Sakakida M, Kishikawa H, Araki E: Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care, 2003; 26: 1507-1512
8. Baynes JW: Role of oxidative stress in development of complication in diabetes. Diabetes, 1991; 40: 405-412
9. Sevanian A, Berliner J, Peterson H, Uptake, metabolism and cytotoxicity of isomeric cholesterol-5,6-epoxides in rabbit aortic endothelial cells. J Lipid Res, 1991; 32: 147-155
10. Boissonneault GA, Hennig B, Wang Y, Ouyang CM, Krahulik L, Cunnup L, Oeltgen PR: Effect of oxysterol-enriched low-density lipoprotein on endothelial barrier function in culture. Low-density lipoproteins. Ann Nutr Metab, 1991; 35: 226-232
11. Boissonneault GA, Hennig B, Ouyang CM: Oxysterols, cholesterol biosynthesis, and vascular endothelial cell monolayer barrier function. Proc Soc Exp Biol Med, 1991; 196: 338-343
12. Sevanian A, Hodis HN, Hwang J, Peterson H: Involvement of cholesterol oxides in the atherogenic action of oxidized LDL. In: G. Bellomo, G. Finardi, E. Maggi, and C. Rice-Evans, Editors. Free radicals, lipoprotein oxidation and atherosclerosis (1st ed.). Eichelieu Press, London, England, 1995; 139-161
13. Smith LL: Review of progress in sterol oxidations: 1987-1995. Lipids, 1996; 31: 453-487
14. Palladini G, Finardi G, Bellomo G: Disruption of actin microfilament organization by cholesterol oxides in 73/73 endothelial cells. Exp Cell Res, 1996; 223: 72-82
15. Deckert V, Perségol L, Viens L, Lizard G, Athias A, Lallemant C, Gambert P, Lagrost L: Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins: Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation, 1997; 95: 723-731
16. Miyashita Y, Shirai K, Ito Y, Watanabe J, Urano Y, Murano T, Tomioka H: Cytotoxicity of some oxysterols on human vascular smooth muscle cells was mediated by apoptosis. J Atheroscler Thromb, 1997; 4: 73-78
17. Brown AJ, Jessup W: Oxysterols and atherosclerosis. Atherosclerosis, 1998; 142: 1-28
18. Deckert V, Brunet A, Lantoine F, Lizard G, Millanvoyevan Brussel E, Monier S, Lagrost L, David-Dufilho M, Gambert P, Devynck MA: Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol, 1998; 18: 1054-1060
19. Urano Y, Shirai K, Watanabe H, Miyasita Y, Hasiguchi S: Vascular smooth muscle cell outgrowth, proliferation, and apoptosis in young and old rats. Atherosclerosis, 1999; 146: 101-105
20. Oyama T, Miyashita Y, Kinoshita K, Watanabe H, Shirai K, Yagima T: Effect of deposited lipids in atheromatous lesions on the migration of vascular smooth muscle cells. J Atheroscler Thromb, 2001; 9: 109-113
21. Council on Cardiovascular Surgery, American Heart Association. Report of the committee for granding of coronary artery disease: a reporting system on patients evaluated for coronary artery disease. Circulation, 1975; 517-538
22. Fridewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
23. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousedian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986; 256: 2835-2838
24. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded ? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 1986; 256: 2823-2828
25. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389
26. Shephard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med, 1995; 333: 1301-1307
27. Miyake Y: Risk factors for non-fatal acute myocardial infarction in middle-aged and older Japanese. Fukuoka Heart Study Group. Jpn Circ J, 2000; 64: 103-109
28. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, Shirai K: Pre-heparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis, 2000; 153: 391-396
29. Hitsumoto T, Yoshinaga K, Aoyagi K, Sakurai T, Kanai M, Uchi T, Noike H, Ohsawa H, Watanabe H, Shirai K: Association between preheparin serum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb, 2002; 9: 163-169
30. Satoh H, Nishino T, Tomita K, Tsutsui H: Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J, 2006; 70: 227-231
31. Tomasik A, Jacheć W, Skrzep-Poloczek B, Wojciechowska C, Tarnawski R, Wodniecki J, Poloński L, Szczurek-Katański K: Impact of baseline level of 7-ketocholesterol on the rate of coronary reintervention in coronary artery disease patients - results of an observational study with questionnaire-based follow up. Med Sci Monit, 2000; 6: 751-758
32. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb, 1991; 11: 298-306
33. Lyons TJ: Lipoprotein glycation and its metabolic consequences. Diabetes, 1992; 41: 67-73
34. Austin MA, Krauss RM: Genetic control of low density-lipoprotein subclasses. Lancet, 1986; 2: 592-595
35. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol, 1994; 5: 339-349
36. Koba S, Hirano T: Small dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intern Med, 2000; 132: 762
37. Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res, 2002; 43: 1363-1379
38. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986; 256: 2835-2838
39. Rhoads GG, Gulbrandsen CL, Kagan A: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med, 1976; 294: 293-298
40. Terasaka N, Wang N, Yvan-Charvet L, Tall AR: High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA, 2007; 104: 15093-15098
41. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
42. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-1143
43. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002; 347: 1557-1565
44. Matsumoto K, Sera Y, Abe Y, Ueki Y, Tominaga T, Miyake S: Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis, 2003; 169: 317-321
45. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004; 109: 647-655
46. Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, Ejiri J, Hirata K, Kawashima S, Hayashi Y, Yokozaki H, Itoh H, Yokoyama M: Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol, 2003; 23: 1398-1404
47. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A: Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem, 1996; 271: 8837-8842
48. Liu Y, Hultén LM, Wiklund O: Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol, 1997; 17: 317-323
49. Leonarduzzi G, Gamba P, Sottero B, Kadl A, Robbesyn F, Calogero RA, Biasi F, Chiarpotto E, Leitinger N, Sevanian A, Poli G: Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radical Biol Med, 2005; 39: 1152-1161
50. Rosklint T, Ohlsson BG, Wiklund O, Norén K, Hultén LM: Oxysterols induce interleukin-1beta production in human macrophages. Eur J Clin Invest, 2002; 32: 35-42
51. Joffre C, Leclère L, Buteau B, Martine L, Cabaret S, Malvitte L, Acar N, Lizard G, Bron A, Creuzot-Garcher C, Bretillon L: Oxysterols induced inflammation and oxidation in primary porcine retinal pigment epithelial cells. Curr Eye Res, 2007; 32: 271-280
52. Terkeltaub R, Boisvert WA, Curtiss LK: Chemokines and atherosclerosis. Curr Opin Lipidol, 1998; 9: 397-405
53. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation, 1999; 99: 420-426